Kuros Biosciences AG (CSBTF)
USD 32.4
(3.09%)
USD 32.4
(3.09%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 33.56 Million CHF | 86.61% |
| 2022 | 17.98 Million CHF | 30.19% |
| 2021 | 13.81 Million CHF | 242.04% |
| 2020 | 4.03 Million CHF | 57.71% |
| 2019 | 2.56 Million CHF | 258.18% |
| 2018 | 715 Thousand CHF | 33.9% |
| 2017 | 534 Thousand CHF | -49.67% |
| 2016 | 1.06 Million CHF | -83.3% |
| 2015 | 6.35 Million CHF | 535.5% |
| 2014 | 1 Million CHF | 0.0% |
| 2013 | 1 Million CHF | -9.09% |
| 2012 | 1.1 Million CHF | -29.98% |
| 2011 | 1.57 Million CHF | -92.97% |
| 2010 | 22.34 Million CHF | 145.38% |
| 2009 | 9.1 Million CHF | -53.82% |
| 2008 | 19.72 Million CHF | -45.03% |
| 2007 | 35.88 Million CHF | 4856.08% |
| 2006 | 724 Thousand CHF | -83.39% |
| 2005 | 4.35 Million CHF | 5.98% |
| 2004 | 4.11 Million CHF | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 15.92 Million CHF | -23.07% |
| 2024 Q2 | 15.92 Million CHF | 0.0% |
| 2023 FY | 33.56 Million CHF | 86.61% |
| 2023 Q2 | 12.86 Million CHF | 100.0% |
| 2023 Q1 | 6.43 Million CHF | -14.91% |
| 2023 Q4 | 20.69 Million CHF | 100.0% |
| 2023 Q3 | 10.34 Million CHF | -19.56% |
| 2022 Q1 | 5.21 Million CHF | 10.23% |
| 2022 FY | 17.98 Million CHF | 30.19% |
| 2022 Q4 | 7.56 Million CHF | 100.0% |
| 2022 Q3 | 3.78 Million CHF | -63.74% |
| 2022 Q2 | 10.42 Million CHF | 100.0% |
| 2021 FY | 13.81 Million CHF | 242.04% |
| 2021 Q3 | 2.36 Million CHF | -73.98% |
| 2021 Q4 | 4.72 Million CHF | 100.0% |
| 2021 Q2 | 9.08 Million CHF | 100.0% |
| 2021 Q1 | 4.54 Million CHF | 65.56% |
| 2020 Q3 | 1.37 Million CHF | 5.95% |
| 2020 Q4 | 2.74 Million CHF | 100.0% |
| 2020 Q2 | 1.29 Million CHF | 100.0% |
| 2020 FY | 4.03 Million CHF | 57.71% |
| 2020 Q1 | 647.5 Thousand CHF | -60.78% |
| 2019 Q3 | 825.5 Thousand CHF | -9.29% |
| 2019 FY | 2.56 Million CHF | 258.18% |
| 2019 Q4 | 1.65 Million CHF | 100.0% |
| 2019 Q2 | 910 Thousand CHF | 100.0% |
| 2019 Q1 | 455 Thousand CHF | 106.35% |
| 2018 Q4 | 220.5 Thousand CHF | 0.0% |
| 2018 Q2 | 137 Thousand CHF | 0.0% |
| 2018 Q3 | 220.5 Thousand CHF | 60.95% |
| 2018 FY | 715 Thousand CHF | 33.9% |
| 2018 Q1 | 137 Thousand CHF | 0.0% |
| 2017 Q1 | 267 Thousand CHF | 8800.0% |
| 2017 Q2 | 267 Thousand CHF | 0.0% |
| 2017 Q3 | - CHF | -100.0% |
| 2017 Q4 | - CHF | 0.0% |
| 2017 FY | 534 Thousand CHF | -49.67% |
| 2016 Q1 | 527.5 Thousand CHF | 825.44% |
| 2016 Q2 | 527.5 Thousand CHF | 0.0% |
| 2016 FY | 1.06 Million CHF | -83.3% |
| 2016 Q3 | 3000.00 CHF | -99.43% |
| 2016 Q4 | 3000.00 CHF | 0.0% |
| 2015 Q1 | 15 Thousand CHF | 0.0% |
| 2015 Q4 | 57 Thousand CHF | 0.0% |
| 2015 FY | 6.35 Million CHF | 535.5% |
| 2015 Q2 | 15 Thousand CHF | 0.0% |
| 2015 Q3 | 57 Thousand CHF | 280.0% |
| 2014 FY | 1 Million CHF | 0.0% |
| 2013 Q4 | 250 Thousand CHF | 0.0% |
| 2013 Q2 | 250 Thousand CHF | 0.0% |
| 2013 Q1 | 250 Thousand CHF | 0.0% |
| 2013 Q3 | 250 Thousand CHF | 0.0% |
| 2013 FY | 1 Million CHF | -9.09% |
| 2012 Q2 | 350 Thousand CHF | 40.0% |
| 2012 Q4 | 250 Thousand CHF | 0.0% |
| 2012 Q3 | 250 Thousand CHF | -28.57% |
| 2012 Q1 | 250 Thousand CHF | 0.0% |
| 2012 FY | 1.1 Million CHF | -29.98% |
| 2011 Q4 | 250 Thousand CHF | -24.7% |
| 2011 Q2 | 389 Thousand CHF | -35.17% |
| 2011 Q1 | 600 Thousand CHF | -4.76% |
| 2011 Q3 | 332 Thousand CHF | -14.65% |
| 2011 FY | 1.57 Million CHF | -92.97% |
| 2010 Q1 | 250 Thousand CHF | -65.03% |
| 2010 FY | 22.34 Million CHF | 145.38% |
| 2010 Q4 | 630 Thousand CHF | 110.0% |
| 2010 Q3 | 300 Thousand CHF | -98.58% |
| 2010 Q2 | 21.16 Million CHF | 8367.6% |
| 2009 Q4 | 715 Thousand CHF | -60.67% |
| 2009 FY | 9.1 Million CHF | -53.82% |
| 2009 Q1 | 250 Thousand CHF | 0.0% |
| 2009 Q2 | 6.32 Million CHF | 2430.0% |
| 2009 Q3 | 1.81 Million CHF | -71.26% |
| 2008 FY | 19.72 Million CHF | -45.03% |
| 2007 FY | 35.88 Million CHF | 4856.08% |
| 2006 FY | 724 Thousand CHF | -83.39% |
| 2005 FY | 4.35 Million CHF | 5.98% |
| 2004 FY | 4.11 Million CHF | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Agentix Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -44224.124% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -5415.632% |
| Biomind Labs Inc. | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -8083.048% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.772% |
| CytoDyn Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -84.235% |
| GB Sciences, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -1637.267% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -14088.367% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 72.702% |
| SQZ Biotechnologies Company | 21.47 Million USD | -56.272% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -33805.085% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -112.794% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -50964.995% |
| Mesoblast Limited | 5.9 Million USD | -468.689% |
| Marizyme, Inc. | 645.81 Thousand USD | -5097.194% |
| Genus plc | 668.8 Million USD | 94.981% |
| Pharming Group N.V. | 245.31 Million USD | 86.318% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -43625.329% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -84833.448% |
| MultiCell Technologies, Inc. | 49.32 USD | -68053427.981% |
| ONE Bio Corp. | 52.29 Million USD | 35.819% |
| RVL Pharmaceuticals plc | 49.72 Million USD | 32.495% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -13.403% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -5918.181% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -47848.571% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -4997.039% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| Enzolytics Inc. | 52.79 Thousand USD | -63472.998% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 97.263% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -23832.916% |
| Genscript Biotech Corporation | 839.52 Million USD | 96.002% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -190377.271% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -3264.05% |
| EV Biologics, Inc. | 48.9 Thousand USD | -68538.037% |
| Q BioMed Inc. | 284.35 Thousand USD | -11703.68% |
| Capstone Therapeutics Corp. | 48.35 Million USD | 30.587% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 76.868% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -101.158% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -3359659.76% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -5336.487% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -14088.367% |
| Affymax, Inc. | 1.36 Million USD | -2351.717% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -330.915% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -6985.048% |
| SYBLEU INC | 11.69 Thousand USD | -286869.904% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -258084.615% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -84799.074% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -907.928% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -403.586% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -3130.414% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -30.26% |
| CSL Limited | 14.8 Billion USD | 99.773% |
| Cellectis S.A. | 755 Thousand USD | -4345.563% |